Lineage Cell Therapeutics, Inc. - LCTX STOCK NEWS

Lineage Cell Therapeutics (LCTX) announced that Cancer Research UK has completed patient enrollment in the Phase 1 clinical trial for VAC2, an allogeneic cancer vaccine designed for non-small cell lung cancer (NSCLC). Lineage has now taken over responsibility for further clinical development of VAC2. Initial clinical results are expected later this year. Lineage's manufacturing improvements aim to prepare VAC2 for future trials, including an Investigational New Drug Application submission to the FDA. This step underlines their commitment to advancing innovative cancer therapies.

Lineage Cell Therapeutics, a clinical-stage biotech company, announced CEO Brian M. Culley will present at NobleCon18, on April 20, 2022, at 4:30 PM ET. The conference will be held at the Hard Rock Hotel & Casino in Hollywood, Florida, from April 19-21. Lineage specializes in allogeneic cell therapies aimed at significant medical needs, with products like OpRegen for macular degeneration and OPC1 for spinal cord injuries. An archived webcast of the presentation will be available from April 21 on the Lineage website.

Lineage Cell Therapeutics, Inc. (LCTX) will present at the 2022 Virtual Growth Conference on March 28, 2022, at 10 AM ET. CEO Brian M. Culley will participate in an Ophthalmology Panel and provide a corporate overview available on demand from the same date. The event, hosted by Maxim Group LLC and M-Vest, requires registration for participation. Lineage focuses on developing allogeneic cell therapies for unmet needs, including therapies for dry age-related macular degeneration and acute spinal cord injuries, with substantial market opportunities.

Lineage Cell Therapeutics (LCTX) has expanded its cell therapy pipeline to include an investigational auditory neuronal cell transplant aimed at treating hearing loss, particularly auditory neuropathy spectrum disorders. The company has filed for intellectual property to support this initiative, which addresses a significant global health issue affecting over 430 million people. CEO Brian Culley highlighted the potential benefits of auditory neuronal transplants and emphasized the efficient development process using existing infrastructure. The initiative follows a recent partnership with Roche and Genentech worth up to $670 million.

Lineage Cell Therapeutics (LCTX) reported full results from a Phase 1/2a clinical study of RG6501 (OpRegen®) for dry age-related macular degeneration (AMD). The therapy is developed in collaboration with Roche and Genentech. Results will be presented at the 2022 ARVO Annual Meeting. The study involved 24 patients across four cohorts, assessing safety and efficacy. No new treatment emergent adverse events were reported, indicating OpRegen has been well tolerated. Currently, there are no FDA or EMA approved treatments for dry AMD, highlighting the potential for OpRegen in a significant market.

Lineage Cell Therapeutics (LCTX) announced an exclusive worldwide collaboration with Roche and Genentech for the development of OpRegen, a retinal cell therapy, valued at up to $670 million. This partnership underscores the validation of Lineage's technology platform. In Q4 2021, total revenues increased to $1.2 million from $0.4 million in 2020, primarily from royalties and licensing fees. However, operating expenses surged to $29.2 million due to OpRegen-related costs, leading to a net loss of $29 million for the quarter. Lineage held $55.7 million in cash and equivalents as of December 31, 2021.

Lineage Cell Therapeutics, Inc. (LCTX) will release its Q4 and full-year 2021 financial results on March 10, 2022, after market close. A conference call will be held on the same day at 4:30 PM ET to discuss these results and provide a business update. LCTX focuses on developing allogeneic cell therapies targeting unmet medical needs, including treatments for age-related macular degeneration and spinal cord injuries. Investors can access the call by phone or via a live webcast on the company’s website.

Lineage Cell Therapeutics (AMEX: LCTX) announced that CEO Brian M. Culley will present at the B. Riley Securities 2022 Virtual Oncology Conference at 2:00 PM Eastern. The presentation will cover updates on the cell therapy pipeline, including clinical development plans for OPC1 and VAC2. Recently, Lineage received a $50 million upfront payment from Genentech for its OpRegen program.

Lineage Cell Therapeutics (LCTX), a clinical-stage biotechnology firm, announced that CEO Brian M. Culley will present at the H.C. Wainwright Bioconnect Virtual Conference. The presentation will be available on demand starting January 10, 2022, at 7:00 AM ET on the company's website. Lineage focuses on developing innovative cell therapies for unmet medical needs, including three leading candidates: OpRegen for dry age-related macular degeneration, OPC1 for acute spinal cord injuries, and VAC2 for non-small cell lung cancer.